HALO Company Profile and Key Details

Q: Who are the executives of HALO?

Mr. Gary GroteChief Commercial OfficerDr. Helen I. Torley M.B. Ch. B., M.R.C.P.Pres, Chief Executive Officer & DirectorDr. Christopher Bryant Ph.D.Chief Manufacturing Officer & Head of Technical OperationsDr. Michael J. LaBarre Ph.D.Senior Vice President & Chief Technical OfficerDr. Steve Knowles MBBSChief Medical OfficerMr. Todd ButlerChief of Staff to the Chief Executive Officer, Vice President & Head of Project ManagementMs. Amy Marinne FoxChief HR OfficerMs. Nicole LaBrosseSenior Vice President & Chief Financial OfficerMr. Mark Snyder Esq.Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.Ms. Tram BuiHead of Investor Relations & Corporation CommunicationsMs. Kristin SchwartzbauerHead of Quality

NASDAQ : HALO

Halozyme Therapeutics

$70.98

-1.06-1.47%

At Close 4:00 PM

59.61

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Halozyme Therapeutics, Inc. (HALO) stock declined over -1.47%, trading at $70.98 on NASDAQ, down from the previous close of $72.04. The stock opened at $71.71, fluctuating between $70.56 and $72.72 in the recent session.

Stock Snapshot

72.04

Prev. Close

8.35B

Market Cap

70.56

Day Low

15.2

P/E Ratio

4.67

EPS (TTM)

2.89

Cash Flow per Share

71.71

Open

117.6M

Number of Shares

72.72

Day High

98.77%

Free Float in %

0.65

Book Value

1.99M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 20, 2026	71.71	72.72	70.56	70.98	2.13M
Feb 19, 2026	73.94	73.94	71.04	72.04	2.97M
Feb 18, 2026	77.64	78.41	71.50	73.23	6.35M
Feb 17, 2026	79.75	81.51	79.17	80.48	2.08M
Feb 13, 2026	77.83	81.19	77.55	79.44	1.74M
Feb 12, 2026	79.31	79.53	76.10	76.92	2.22M
Feb 11, 2026	80.51	80.57	78.88	79.51	1.42M
Feb 10, 2026	80.86	81.64	80.13	80.22	1.44M
Feb 09, 2026	82.00	82.22	80.41	80.48	1.64M
Feb 06, 2026	79.01	81.36	78.76	81.23	2.24M
Feb 05, 2026	77.49	79.39	77.49	78.42	2.48M
Feb 04, 2026	77.24	78.27	76.11	77.93	2.47M
Feb 03, 2026	74.82	77.20	74.28	76.48	3.77M
Feb 02, 2026	72.00	74.47	71.22	74.45	2.08M
Jan 30, 2026	73.34	74.48	71.30	71.71	2.04M
Jan 29, 2026	72.95	73.36	70.79	73.34	2.2M
Jan 28, 2026	70.95	73.21	70.10	72.83	2.54M
Jan 27, 2026	69.48	71.49	69.48	70.22	1.01M
Jan 26, 2026	69.01	71.39	68.85	69.87	1.37M
Jan 23, 2026	70.94	71.90	69.10	69.22	1.77M

Contact Details

San Diego, CA 92121

United States

https://www.halozyme.com 858 794 8889

About Company

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Stock Peers

ARGX

-2.85-0.34%

argenx SE$844.41 REGN

-1.77-0.23%

Regeneron Pharmaceuticals, Inc.$779.67 VRTX

7.63+1.63%

Vertex Pharmaceuticals Incorporated$476.90 UTHR

-7.1-1.48%

United Therapeutics Corporation$473.42 MDGL

-1.86-0.43%

Madrigal Pharmaceuticals, Inc.$435.01 ALNY

-3.18-0.94%

Alnylam Pharmaceuticals, Inc.$336.19 PRAX

3.67+1.11%

Praxis Precision Medicines, Inc.$335.28 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-0.87-0.33%

Krystal Biotech, Inc.$261.80 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Halozyme Therapeutics, Inc. (NASDAQ:HALO) closed at $70.98 USD, losing -$1.06 (-1.47%) from the previous close of $72.04. The stock is currently mid-range between its 52-week high and low $47.50 and $82.22. With a market capitalization of about $8.35 billion, Halozyme Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.98). Key stats such as the average daily volume over the past year has been around 2.17 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Halozyme Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Helen I. Torley, the company employs approximately 350 people and listed since March 16, 2004. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -5.92%, SMA50 -0.57%, SMA200 7.87%). The stock’s 14-day RSI is 41.79 (neutral), while the ATR of 2.86 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -13.67% below its high and over 49.43% above its low. Average 10-day trading volume of 2.91 million shares is slightly above the 3-month average of 2.17 million, indicating heightened recent market interest.

Valuation Metrics

Halozyme Therapeutics, Inc. trades at a P/E ratio of 26.36, slightly below the S&P 500 average, with a price-to-sales ratio of 5.98 and a price-to-book ratio of 171.11 reflecting a rich premium to book value. The P/FCF stands at 12.95, also above market averages. Compared to sector medians, Halozyme Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Halozyme Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $116.02. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Halozyme Therapeutics, Inc. generated EPS of $2.49 over the past year. Five-year average earnings growth is 22.89%. Wall Street analysts project EPS growth of 36.58% annually over the next five years. The latest quarter delivered EPS of $1.43. The next quarter is forecast at $1.53. Next year's EPS is expected at $49.77. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 9 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $92.00 to $56.00. The high target offers 29.61% upside. The low target suggests -21.1% downside. The mean target is $79.80. This offers 12.43% upside. Halozyme Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 03, 2025, missed forecasts by -12.27%. The prior quarter beat by 25.2%. Over the last six quarters, Apple has recorded several small beats. These include 19.74% in August 06, 2024.

Shareholding & Insider Activity

Halozyme Therapeutics, Inc. has 116.97 million shares outstanding. The public float is 115.51 million shares, elevated short interest at 11.86% of float. This equals 9.93 million shares. The short ratio is 6.61 days. Institutional investors hold 103.89% of the float. Insiders own 1.17%. Torley Helen holds 708.72 thousand shares, MATSUI CONNIE has 181.98 thousand shares and Kelley Kenneth J has 179.83 thousand shares. Over the past six months, insider transactions show net selling. They sold 84.27 thousand shares across 21 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Halozyme Therapeutics generated $829.25M in revenue, or $6.18 per share. Gross margin was 76.80%, operating margin 40.71%, and net profit margin 33.96%. Returns are exceptional, with ROA at 16.25% and ROE at 336.00%.
On valuation metrics, Halozyme Therapeutics trades at a P/E of 26.36, P/S of 5.98 and P/B of 171.11. The current ratio is 4.66 and quick ratio is 3.66. Operationally, the company’s inventory turnover is 1.43 and cash conversion cycle is 340.53 days.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Halozyme Therapeutics posted revenue of $829.25M, down slightly from $660.12M in the prior quarter. Gross profit was $636.89M (margin 76.80%). Operating income was $337.57M (margin 40.7%). Net income was$281.59M (EPS $2.13).
The company ended the quarter with $336.00M in cash and short-term investments, a total debt of $1.50B, and net debt of $1.38B. Total assets were $1.73B, with equity of $83.81M. Financials further reflected stability, with operating cash flow of $388.57M, free cash flow of $373.28M, and capital expenditures of - $15.29M.

Price Forecast & Outlook

Our AI price prediction model suggests that Halozyme Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.33%, with price expected at $75.47 by March 06, 2026, within a range of $72.25 to $78.60 3-Month Outlook: Projected fall of -9.62%, reaching $64.15 by May 21, 2026, with a range of $63.02 to $65.16. 1-Year Outlook: Projected gain of 17.72%, with price at $83.56 by February 19, 2027, within a range of $80.25 to $86.24.

Key Takeaways

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares are flat 4.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Halozyme Therapeutics, Inc. trading at a premium to the broader market with a P/E of 26.36. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $61.04, suggesting -14.0% downside. Our AI forecast model points to short-term strength (6.33% over two weeks), a medium-term fall (-9.62% over three months), and a longer-term gain (17.72% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Halozyme Therapeutics, Inc. (HALO) stock price?

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock price is $70.98 in the last trading session. During the trading session, HALO stock reached the peak price of $72.72 while $70.56 was the lowest point it dropped to. The percentage change in HALO stock occurred in the recent session was -1.47% while the dollar amount for the price change in HALO stock was - $1.06.

HALO's industry and sector of operation?

The NASDAQ listed HALO is part of Biotechnology industry that operates in the broader Healthcare sector. Halozyme Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HALO?

Mr. Gary Grote
Chief Commercial Officer
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Pres, Chief Executive Officer & Director
Dr. Christopher Bryant Ph.D.
Chief Manufacturing Officer & Head of Technical Operations
Dr. Michael J. LaBarre Ph.D.
Senior Vice President & Chief Technical Officer
Dr. Steve Knowles MBBS
Chief Medical Officer
Mr. Todd Butler
Chief of Staff to the Chief Executive Officer, Vice President & Head of Project Management
Ms. Amy Marinne Fox
Chief HR Officer
Ms. Nicole LaBrosse
Senior Vice President & Chief Financial Officer
Mr. Mark Snyder Esq.
Senior Vice President, Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Ms. Tram Bui
Head of Investor Relations & Corporation Communications
Ms. Kristin Schwartzbauer
Head of Quality

How HALO did perform over past 52-week?

HALO's closing price is 49.43% higher than its 52-week low of $47.50 where as its distance from 52-week high of $82.22 is -13.67%.

How many employees does HALO have?

Number of HALO employees currently stands at 350.

Link for HALO official website?

Official Website of HALO is: https://www.halozyme.com

How do I contact HALO?

HALO could be contacted at phone 858 794 8889 and can also be accessed through its website. HALO operates from 11388 Sorrento Valley Road, San Diego, CA 92121, United States.

How many shares of HALO are traded daily?

HALO stock volume for the day was 1.99M shares. The average number of HALO shares traded daily for last 3 months was 2.17M.

What is the market cap of HALO currently?

The market value of HALO currently stands at $8.35B with its latest stock price at $70.98 and 117.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	350
Beta	0.98
Sales or Revenue	$829.25M
5Y Sales Change%	4.937%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

HALO Company Profile and Key Details

Halozyme Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook